New drug aims to keep AML away after transplant
Disease control
Recruiting now
This Phase 3 trial tests whether mocravimod, taken as a pill, can prevent acute myeloid leukemia (AML) from returning after a stem cell transplant. About 366 adults with high-risk AML will receive either mocravimod or a placebo for up to two years. The main goal is to see if the …
Phase: PHASE3 • Sponsor: Priothera SAS • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC